Consequently, we designed and developed a TME-responsive, bovine serum albumin-folate acid (BSA-FA) functionalized hybrid nanoplatform (IrO2@ZIF-8/BSA-FA (Ce6), denoted as IZBFC) in the treatment of cancers, which displays high drug loading capacity and are capable of overcome the shortfalls of Ce6, thereby achieving synergistic therapeutic effects of PTT-PDT for tumor eradication. Here, ALB is linked to cancer.